UniProtKB/SwissProt variant VAR

Variant information

Variant position:

322

The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:

Disease [Disclaimer]

The variants are classified into three categories: Disease, Polymorphism and Unclassified.

Disease: Variants implicated in disease according to literature reports.
Polymorphism: Variants not reported to be implicated in disease.
Unclassified: Variants with uncertain implication in disease according to literature reports. Evidence against or in favor of a pathogenic role is limited and/or conflicting.

Residue change:

From Alanine (A) to Aspartate (D) at position 322 (A322D, p.Ala322Asp).

Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:

Change from small size and hydrophobic (A) to medium size and acidic (D)

The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:

-2

The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:

Lowest score: -4 (low probability of substitution).
Highest score: 11 (high probability of substitution).

More information can be found on the following page

Involvement in disease:

Juvenile myoclonic epilepsy 5 (EJM5) [MIM:611136]: A subtype of idiopathic generalized epilepsy. Patients have afebrile seizures only, with onset in adolescence (rather than in childhood) and myoclonic jerks which usually occur after awakening and are triggered by sleep deprivation and fatigue. {ECO:0000269|PubMed:11992121}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.

The name and a short description of the disease associated with the variant. For more information about the disease, the user can refer to OMIM, following the link provided after the disease acronym.

Variant description:

In EJM5.

Any additional useful information about the variant.

Other resources:

Links to websites of interest for the variant.

Variant rs121434579 [ dbSNP | Ensembl ]

Sequence information

Variant position:

322

The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:

456

The length of the canonical sequence.

Location on the sequence:

NSLPKVAYATAMDWFIAVCY A FVFSALIEFATVNYFTKRGY

The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation:

The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         NSLPKVAYATAMDWFIAVCYAFVFSALIEFATVNYFTKRGY

Mouse                         NSLPKVAYATAMDWFIAVCYAFVFSALIEFATVNYFTKRGY

Rat                           NSLPKVAYATAMDWFIAVCYAFVFSALIEFATVNYFTKRGY

Bovine                        NSLPKVAYATAMDWFIAVCYAFVFSALIEFATVNYFTKRGY

Chicken                       NSLPKVAYATAMDWFIAVCYAFVFSALIEFATVNYFTKRGY

Sequence annotation in neighborhood:

The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:

Type: the type of sequence feature.
Positions: endpoints of the sequence feature.
Description: contains additional information about the feature.

Type	Positions	Description
Chain	28 – 456	Gamma-aminobutyric acid receptor subunit alpha-1
Transmembrane	313 – 334	Helical
Mutagenesis	333 – 333	T -> A. Reduced potentiation and activation by the agonist alphaxalone.
Helix	312 – 336

Literature citations

Mutation of GABRA1 in an autosomal dominant form of juvenile myoclonic epilepsy.
Cossette P.; Liu L.; Brisebois K.; Dong H.; Lortie A.; Vanasse M.; Saint-Hilaire J.-M.; Carmant L.; Verner A.; Lu W.-Y.; Tian Wang Y.; Rouleau G.A.;
Nat. Genet. 31:184-189(2002)
Cited for: VARIANT EJM5 ASP-322;

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P14867: Variant p.Ala322Asp